tiprankstipranks
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
US Market

Adaptimmune Therapeutics (ADAP) Income Statement

Compare
847 Followers

Adaptimmune Therapeutics Income Statement

Last quarter (Q3 2024), Adaptimmune Therapeutics's total revenue was $40.90M, an increase of 458.83% from the same quarter last year. In Q3, Adaptimmune Therapeutics's net income was $-17.62M. See Adaptimmune Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 60.28M$ 27.15M$ 6.15M$ 3.96M$ 1.12M
Gross Profit
$ 50.42M$ -100.58M$ -104.94M$ -87.61M$ -96.38M
Operating Expenses
$ 188.42M$ 191.11M$ 168.40M$ 137.36M$ 140.89M
Depreciation and Amortization
$ 9.84M$ 6.07M$ 6.57M$ 7.65M$ 8.04M
EBITDA
$ -128.20M$ -155.59M$ -155.68M$ -125.81M$ -131.76M
Operating Income
$ -138.04M$ -163.97M$ -162.25M$ -133.41M$ -139.77M
Other Income/Expenses
$ 25.50M$ -1.29M$ 4.95M$ 3.48M$ 2.85M
Pretax Income
$ -112.53M$ -162.96M$ -157.30M$ -129.93M$ -136.92M
Net Income
$ -113.87M$ -165.46M$ -158.09M$ -130.09M$ -137.16M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -0.09$ -1.03$ -1.01$ -0.91$ -1.31
Diluted EPS
$ -0.09$ -1.03$ -1.01$ -0.91$ -1.31
Weighted Average Shares Outstanding
1.21B 161.21M 155.81M 142.46M 104.97M
Weighted Average Shares Outstanding (Diluted)
1.21B 161.21M 155.81M 142.46M 104.97M
Currency in USD

Adaptimmune Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis